Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, April 23, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
David Nierengarten Reiterated (TCRX) at Buy and Held Target at $10 on, Apr 23rd, 2024
David Nierengarten of Wedbush, Reiterated "TScan Therapeutics, Inc." (TCRX) at Buy and Held Target at $10 on, Apr 23rd, 2024.
David has made no other calls on TCRX in the last 4 months.
There are 2 other peers that have a rating on TCRX. Out of the 2 peers that are also analyzing TCRX, 0 agree with David's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with David
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $15 on, Thursday, March 7th, 2024
- Peter Lawson of "Barclays" Maintained at Buy with Increased Target to $9 on, Thursday, March 7th, 2024
